FOS and arthritic joint disease: Multiple drugs (e.g., CKD-506, T-5224, Roflumilast) are under investigation to disrupt this specific interaction of AP-1 at the MMP3 promoter, and AP-1 signaling targets more broadly, in models of arthritis as well as clinical trials of RA patients116.